Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,206 questions in 117 reviews · Common Mental Disorders
current versionsNo studies 387 · 17.5%Ungraded 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Paroxetine vs agomelatine Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.25 [0.78, 2.01] | 1 study · 284 participants | Moderate |
Paroxetine vs milnacipran Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs milnacipran Failure to remit at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.92 [0.57, 1.49] | 1 study · 302 participants | Moderate |
Paroxetine vs milnacipran SMD at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 1 study · 299 participants | Moderate |
Paroxetine vs milnacipran Failure to complete ‐ any cause ‐ · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.17 [0.67, 2.3] | 2 studies · 343 participants | Moderate |
Paroxetine vs milnacipran Participants with at least some Side Effects · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.69 [0.41, 1.15] | 1 study · 302 participants | Moderate |
Paroxetine vs mirtazapine Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.2 [0.9, 1.61] | 4 studies · 766 participants | Moderate |
Paroxetine vs mirtazapine Failure to respond at 1‐4 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 2.39 [1.42, 4.02] | 3 studies · 726 participants | Moderate |
Paroxetine vs mirtazapine Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.41 [0.81, 2.48] | 3 studies · 726 participants | Moderate |
Paroxetine vs mirtazapine Failure to remit at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.52 [1.13, 2.06] | 4 studies · 766 participants | Moderate |
Paroxetine vs mirtazapine SMD at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 1 study · 246 participants | Moderate |
Paroxetine vs agomelatine Failure to respond at 1‐4 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs mirtazapine Failure to complete ‐ any cause ‐ · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.26 [0.91, 1.74] | 3 studies · 726 participants | Moderate |
Paroxetine vs mirtazapine Participants with at least some Side Effects · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.07 [0.76, 1.5] | 3 studies · 726 participants | Moderate |
Paroxetine vs nefazodone Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.31 [0.07, 1.25] | 1 study · 40 participants | Moderate |
Paroxetine vs nefazodone Failure to respond at 1‐4 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs nefazodone Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.64 [0.17, 2.38] | 1 study · 40 participants | Moderate |
Paroxetine vs nefazodone Failure to remit at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs nefazodone SMD at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 2 studies · 235 participants | Moderate |
Paroxetine vs nefazodone Failure to complete ‐ any cause ‐ · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.53 [0.11, 2.6] | 1 study · 40 participants | Moderate |
Paroxetine vs nefazodone Participants with at least some Side Effects · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.69 [0.34, 1.4] | 1 study · 206 participants | Moderate |
Paroxetine vs reboxetine Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.82 [0.66, 1.02] | 3 studies · 1369 participants | Moderate |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Reduction of panic symptoms: Panic Disorder Severity Scale (PDSS) (high=poor, data skewed) PDSS, Scale from: 0 to 28) · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Acceptability: dropouts for any reason number of dropouts · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | no estimate extracted | 2 studies · 40 participants | Very low |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Acceptability: dropouts for adverse effects number of dropouts · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | RD 0 | 2 studies · 40 participants | Very low |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Improvment of social function: Self‐reported social adaptation scale (SASS) (low=poor), acute effect SASS. Scale from: 0 to 60. · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Quality of life (such as the SF‐36 Health Survey (Ware 1992) · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
rTMS + pharmacotherapy vs sham rTMS + pharmacotherapy Safety of rTMS: Frequency of rTMS side effects (values are percentages) self‐reported questionnaire · participants with panic disorder Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
Psychological intervention vs control Reduction on a scale of psychological distress— · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | 4 studies · 86 participants | Very low |
Psychological intervention vs control Adverse events · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | NR | No studies |
Psychological intervention vs control Reduction in post‐traumatic stress symptoms— · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | 4 studies · 86 participants | Very low |
Psychological intervention vs control Improvement in quality of life— · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | NR | No studies |
Psychological intervention vs control Improvement in participation · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | NR | No studies |
Psychological intervention vs control Improvement in family or social relationships · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | NR | No studies |
Psychological intervention vs control Satisfaction with treatment · people of any age who have survived any type of torture Psychological, social and welfare interventions for psychological health and well‐being of torture survivors (2014) · Cochrane | no estimate extracted | NR | No studies |
Tricyclic antidepressants vs placebo Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (SCL‐90‐R Somatisation Subscore, VAS) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 239 participants | Low |
New‐generation antidepressants vs placebo Anxiety (post‐treatment score on self report and clinician‐rated scales) Clinician‐rated scales (HARS) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 163 participants | Very low |
New‐generation antidepressants vs placebo Depression (post‐treatment score on self report and clinician‐rated scales) Different clinician‐rated scales (HDRS, MADRS) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 163 participants | Very low |
New‐generation antidepressants vs placebo Adverse effects (drop‐outs due to adverse effects) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | RR 2.26 [0.52, 9.81] | 2 studies · 163 participants | Low |
New‐generation antidepressants vs placebo Treatment response (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (PHQ‐15, CGI ‐ Improvement Scale) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | RR 2 [0.9, 4.43] | 2 studies · 163 participants | Very low |
New‐generation antidepressants vs placebo Functional disability and quality of life (post‐treatment score on self report scales) Different self report scales (SF‐36, SDS) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 163 participants | Very low |
Natural products vs placebo Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (SOMS‐7, SCL‐90‐R Somatisation Subscore) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 322 participants | Low |
Natural products vs placebo Acceptability (all‐cause drop‐outs4) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | RR 0.85 [0.4, 1.78] | 3 studies · 506 participants | Low |
Natural products vs placebo Anxiety (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HARS, VAS) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 321 participants | Low |
Natural products vs placebo Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 2 studies · 321 participants | Low |
Natural products vs placebo Adverse effects (drop‐outs due to adverse effects4) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | RR 0.54 [0.08, 3.5] | 3 studies · 506 participants | Low |
Tricyclic antidepressants vs placebo Acceptability (all‐cause drop‐outs) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
Natural products vs placebo Treatment response (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (PHQ‐15, CGI ‐ Improvement Scale) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | RR 1.77 [1.34, 2.34] | 2 studies · 324 participants | Very low |
Natural products vs placebo Functional disability and quality of life (post‐treatment score on self report scales) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
Tricyclic antidepressants vs another medication Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (VAS‐Pain, SCL‐90‐R Somatisation Subscore) · somatoform disorders in adults Pharmacological interventions for somatoform disorders in adults (2014) · Cochrane | no estimate extracted | 3 studies · 177 participants | Low |